|
|
Michael P. Arlotto, PhD
Senior Vice President of Emerging Biotech for NovaQuest
Michael P. Arlotto, PhD, Senior Vice President of Emerging Biotech for NovaQuest, applies his expertise in finding innovative financial solutions to emerging biotechnology customers, allowing them to bring new products to market faster and maximize product sales. Early on in his career with Quintiles, Dr. Arlotto handled projects for all North American Clinical Development Services, managing a staff of about 250 research professionals in multiple locations in the United States and Canada.
Prior to joining Quintiles in 1997, Dr. Arlotto implemented an in vitro metabolism laboratory, creating a liver microsomal library and developing liver-slice methodology for Bayer Corp. As Director of Scientific Planning and Development for Dallas Biomedical, he directed research projects in oncology, immunology, biochemistry and molecular biology. Previously, as a research scientist, he worked on the application of recombinant enzymes for in vitro drug metabolism and toxicology testing, among other projects.
Dr. Arlotto received a bachelor’s degree in toxicology from the Philadelphia College of Pharmacy and Science before earning a doctorate in toxicology from Kansas University Medical Center. He completed a postdoctoral fellowship at Oak Ridge Associated Universities’ National Center for Toxicology Research in Arkansas. Over the years, he has acquired additional executive and applied-science training through numerous short courses at universities and technology centers around the country. Dr. Arlotto has published dozens of abstracts and articles in research journals and has patented a generation of radioactive oxidation products.
|